This mini-review assessed the effects of compliance therapy on compliance with antipsychotic medicine. The author concluded that there was insufficient evidence to assess compliance therapy and that further good-quality research is required. There were limitations to this review but, overall, the author's conclusions appear to reflect the poor quality of the included studies.
Data extraction
The author did not state how the data were extracted for the review, or how many reviewers performed the data extraction. For each study, the mean (with standard deviation, SD) baseline, post-intervention and 12-month scores of compliance and symptoms were extracted for continuous data; where reported, odds ratio (ORs) with 95% confidence intervals (CIs) were extracted for dichotomous data. Data for the outcome measures were extracted at baseline, postintervention and follow-up.
Methods of synthesis
How were the studies combined?
The studies were combined in a narrative.
How were differences between studies investigated?
Differences between the studies were discussed in detail.
Results of the review
Two RCTs (n=130) were included.
Both studies were of poor quality. Methodological flaws included: lack of description of treatment regimens; inadequate information on patient characteristics; lack of clarity about the blinding of assessments; potential detection bias in methods used to assess compliance; potential observer bias in the assessment of symptoms; lack of information on the uptake of booster sessions; lack of power calculations; inadequate information on the scales used to assess compliance; lack of clarity about the handling of drop-outs; and potentially biased methods used to deal with drop-outs.
Both studies recruited patients from limited geographical areas and the generalisability of the results was limited.
Compliance.
One unblinded RCT (n=74 at baseline, n=66 at 12 months) reported that compliance therapy significantly improved compliance at 12 months compared with control. The ratings on a scale of 1 to 7 were 3.7 (SD=1.2) at baseline, improving to 5.5 (SD=1.8) at 12 months, with compliance therapy versus 4.1 (SD=1.2) at baseline, worsening to 3.6 (SD=2.1) at 12 months, with control; the mean difference the 19%. One subsequent report stated that the P-value for treatment difference was less than 0.001.
The other single-blinded RCT (the review author stated there were inconsistencies in the number analysed at 1 year: n=56 at baseline and 6 dropped out during follow-up, but 56 were analysed) reported no statistically significant difference between compliance and control for compliance. The OR of being compliant at baseline was 2.267 (95% CI: 0.47, 11.41), favouring the group allocated to compliance therapy, while the OR of being compliant at 12 months was 0.65 (95% CI: 0.2, 2.11), favouring the compliance treatment group.
Symptoms.
Neither study reported any statistically significant difference in symptoms between treatments. One study reported a mean BPRS (range: 7 to 49; reduction suggests improvement) of 20.3 (SD=7.6) at baseline, improving to 13.8 (SD=6.3) at 12 months, for the group allocated to compliance therapy versus 19.2 (SD=6.6) at baseline, improving to 15.3 (SD=6.2) at 12 months, for the group allocated to control. The second study reported a mean PANSS (range: 7 to 210; reduction suggests improvement) of 71 (SD=22) at baseline, improving to 58.2 (SD=17) at 12 months, for the group allocated to compliance therapy versus 66 (SD=17) at baseline, improving to 52.1 (SD=21) at 12 months, for the group allocated to control; this resulted in a non significant difference of 6.1 (95% CI: -4.7, 16.9, P=0.26) between treatment groups at 12 months.
